China Medical System Holdings Limited
0867
Classement en actions
#4721
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Prix de l'action
$1.31
Capitalisation boursière
$3.19B
Changement (1 jour)
-1.25%
Changement (1 an)
-22.74%
Pays
HK
Échange China Medical System Holdings Limited (0867)
Catégorie
Healthcare
Ratio P/E pour China Medical System Holdings Limited (0867)
Ratio P/E au October 2026 TTM : 14.33
Selon les derniers rapports financiers et le cours de l'action de China Medical System Holdings Limited, le ratio P/E actuel (TTM) est de 14.33. À la fin de l’année 2023, le P/E de l’entreprise était de 12.62.
Historique du ratio P/E pour China Medical System Holdings Limited de 2006 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 14.33 | 34.83% |
| 2024 | 10.63 | -15.81% |
| 2023 | 12.62 | 54.59% |
| 2022 | 8.16 | -5.85% |
| 2021 | 8.67 | 21.84% |
| 2020 | 7.12 | -43.87% |
| 2019 | 12.68 | 47.67% |
| 2018 | 8.59 | -61.87% |
| 2017 | 22.52 | 13.35% |
| 2016 | 19.87 | -16.07% |
| 2015 | 23.67 | 0.72% |
| 2014 | 23.50 | -6.23% |
| 2013 | 25.06 | 14.26% |
| 2012 | 21.93 | 29.37% |
| 2011 | 16.96 | -48.68% |
| 2010 | 33.04 | -0.72% |
| 2009 | 33.28 | 1,346.58% |
| 2008 | 2.30 | -36.83% |
| 2007 | 3.64 | -49.59% |
| 2006 | 7.22 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 143.92% |
IN
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.